Schedule 13G ownership disclosure

Akers Biosciences, Inc.

Security class unavailable · CUSIP: 00973E409

Event date: 2021-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
7,427,625
Percent of class
1.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-22-006668
Form type
SC 13G/A
Filer
BioLineRx Ltd.
CIK
CIK 1498403
Filed
Feb 11, 2022
Reporting period
Dec 31, 2021
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub